The Cost-Effectiveness of an Advanced Hybrid Closed-Loop System Compared to Standard Management of Type 1 Diabetes in a Singapore Setting

被引:1
作者
Gardner, Daphne [1 ]
Lakkad, Mrinmayee [2 ]
Qiu, Zhiyu [3 ]
Inoue, Yuta [2 ]
Chandran, Suresh Rama [1 ]
Wherry, Kael [2 ]
机构
[1] Singapore Gen Hosp, Dept Endocrinol, Singapore, Singapore
[2] Medtron Diabet, Northridge, CA USA
[3] Medtron Singapore, Singapore, Singapore
关键词
Advanced hybrid closed-loop system; Cost-effectiveness; Cost of days off work; Type; 1; diabetes; Singapore; DAILY INSULIN INJECTIONS; QUALITY-OF-LIFE; GLYCEMIC CONTROL; PUMP THERAPY; ADULTS; HYPOGLYCEMIA; REIMBURSEMENT; MULTICENTER; VALIDATION; PREVENTION;
D O I
10.1089/dia.2023.0455
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background: Despite advances in technology, glycemic outcomes in people with type 1 diabetes (T1D) remain suboptimal. The MiniMed 780G (MM780G) advanced hybrid closed-loop (AHCL) system is the latest technology for T1D management with established safety and efficacy. This study explores the cost-effectiveness of MM780G AHCL compared against multiple daily injections (MDI) plus intermittently scanned continuous glucose monitor (isCGM).Methods: A cost-utility analysis was conducted, simulating lifetime outcomes for 1000 T1D individuals, with baseline hemoglobin A1c of 8.4%, using the IQVIA Core Diabetes Model (CDM) v9.5. A Singapore health care payer perspective was taken with 2023 costs applied. Treatment effects were taken from the ADAPT study and treatment-related events from a combination of sources. T1D complication costs were derived from local literature, and health state utilities and disutilities from published literature. Scenario analyses and probabilistic sensitivity analyses (PSAs) explored uncertainty. Cost-effectiveness was assessed based on willingness-to-pay (WTP) thresholds set to Singapore Dollars (SGD) 45,000 (United States Dollars [USD] 33,087) per quality-adjusted life year (QALY) and Singapore's gross domestic product (GDP) per capita of SGD 114,165 (USD 83,941) per QALY.Results: A switch from MDI plus isCGM to MM780G resulted in expected gains in life-years (+0.78) and QALYs (+1.45). Cost savings through reduction in T1D complications (SGD 25,465; USD 18,723) partially offset the higher treatment costs in the AHCL arm (+SGD 74,538; +USD 54,805), resulting in an estimated incremental cost-effectiveness ratio of SGD 33,797 (USD 24,850) per QALY gained. Findings were robust, with PSA outputs indicating 81% and 99% probabilities of cost-effectiveness at the stated WTP thresholds.Conclusion: MM780G is a cost-effective option for people with T1D managed in a Singapore setting.
引用
收藏
页码:324 / 334
页数:11
相关论文
共 68 条
  • [1] Agency for Care Effectiveness, 2022, Medical Technologies Evaluation Methods and Process Guide
  • [2] Agency for Care Effectiveness (ACE), OPPORTUNITIES PATIEN
  • [3] American Diabetes Association (ADA), TRANSITIONING PATIEN
  • [4] Comparison of MiniMed 780G system performance in users aged younger and older than 15 years: Evidence from 12 870 real-world users
    Arrieta, Arcelia
    Battelino, Tadej
    Scaramuzza, Andrea E.
    Da Silva, Julien
    Castaneda, Javier
    Cordero, Toni L.
    Shin, John
    Cohen, Ohad
    [J]. DIABETES OBESITY & METABOLISM, 2022, 24 (07) : 1370 - 1379
  • [5] Clinical Targets for Continuous Glucose Monitoring Data Interpretation: Recommendations From the International Consensus on Time in Range
    Battelino, Tadej
    Danne, Thomas
    Bergenstal, Richard M.
    Amiel, Stephanie A.
    Beck, Roy
    Biester, Torben
    Bosi, Emanuele
    Buckingham, Bruce A.
    Cefalu, William T.
    Close, Kelly L.
    Cobelli, Claudio
    Dassau, Eyal
    DeVries, J. Hans
    Donaghue, Kim C.
    Dovc, Klemen
    Doyle, Francis J.
    Garg, Satish
    Grunberger, George
    Heller, Simon
    Heinemann, Lutz
    Hirsch, Irl B.
    Hovorka, Roman
    Jia, Weiping
    Kordonouri, Olga
    Kovatchev, Boris
    Kowalski, Aaron
    Laffel, Lori
    Levine, Brian
    Mayorov, Alexander
    Mathieu, Chantal
    Murphy, Helen R.
    Nimri, Revital
    Norgaard, Kirsten
    Parkin, Christopher G.
    Renard, Eric
    Rodbard, David
    Saboo, Banshi
    Schatz, Desmond
    Stoner, Keaton
    Urakami, Tatsuiko
    Weinzimer, Stuart A.
    Phillip, Moshe
    [J]. DIABETES CARE, 2019, 42 (08) : 1593 - 1603
  • [6] Effect of Continuous Glucose Monitoring on Glycemic Control in Adults With Type 1 Diabetes Using Insulin Injections The DIAMOND Randomized Clinical Trial
    Beck, Roy W.
    Riddlesworth, Tonya
    Ruedy, Katrina
    Ahmann, Andrew
    Bergenstal, Richard
    Haller, Stacie
    Kollman, Craig
    Kruger, Davida
    McGill, Janet B.
    Polonsky, William
    Toschi, Elena
    Wolpert, Howard
    Price, David
    [J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2017, 317 (04): : 371 - 378
  • [7] Bergenstal RM, 2021, LANCET, V397, P208, DOI 10.1016/S0140-6736(20)32514-9
  • [8] Safety and Glycemic Outcomes During the MiniMed™ Advanced Hybrid Closed-Loop System Pivotal Trial in Adolescents and Adults with Type 1 Diabetes
    Carlson, Anders L.
    Sherr, Jennifer L.
    Shulman, Dorothy, I
    Garg, Satish K.
    Pop-Busui, Rodica
    Bode, Bruce W.
    Lilenquist, David R.
    Brazg, Ron L.
    Kaiserman, Kevin B.
    Kipnes, Mark S.
    Thrasher, James R.
    Reed, John H. Chip
    Slover, Robert H.
    Philis-Tsimikas, Athena
    Christiansen, Mark
    Grosman, Benyamin
    Roy, Anirban
    Vella, Melissa
    Jonkers, Richard A. M.
    Chen, Xiaoxiao
    Shin, John
    Cordero, Toni L.
    Lee, Scott W.
    Rhinehart, Andrew S.
    Vigersky, Robert A.
    [J]. DIABETES TECHNOLOGY & THERAPEUTICS, 2022, 24 (03) : 178 - 189
  • [9] Sustained Impact of Real-time Continuous Glucose Monitoring in Adults With Type 1 Diabetes on Insulin Pump Therapy: Results After the 24-Month RESCUE Study
    Charleer, Sara
    De Block, Christophe
    Nobels, Frank
    Radermecker, Regis P.
    Lowyck, Ine
    Mullens, Annelies
    Scarniere, Denis
    Spincemaille, Katrien
    Strivay, Marie
    Weber, Eric
    Taes, Youri
    Vercammen, Chris
    Keymeulen, Bart
    Mathieu, Chantal
    Gillard, Pieter
    [J]. DIABETES CARE, 2020, 43 (12) : 3016 - 3023
  • [10] Quality of Life and Glucose Control After 1 Year of Nationwide Reimbursement of Intermittently Scanned Continuous Glucose Monitoring in Adults Living With Type 1 Diabetes (FUTURE): A Prospective Observational Real-World Cohort Study
    Charleer, Sara
    De Block, Christophe
    Van Huffel, Liesbeth
    Broos, Ben
    Fieuws, Steffen
    Nobels, Frank
    Mathieu, Chantal
    Gillard, Pieter
    [J]. DIABETES CARE, 2020, 43 (02) : 389 - 397